Turnover: 53.7 billion EUR (2022)

Country: Germany

Description : Of German origin, Bayer inaugurated its first pharmaceutical department in 1888, 25 years after its creation. 30% of the Bayer group's revenues come from its health subsidiary, with leading products in the anticoagulant (Xarelto) and anticancer (Stivarga, Xofigo) markets

Bayer is expanding its presence in the herbal medicine market in the early 2010s by acquiring Steigerwald in 2013. Steigerwald specializes in analgesic, anti-inflammatory and digestive products like Iberogast. Created in the late 1950s, consisting of 9 essential plants and distributed in 30 countries in 2013, Iberogast allows Bayer to invest significantly in the herbal medicine market

The Consumer Health division generated sales of €159.4 million in 2019, or 12.1% of total sales. This division includes vitamins and minerals, dermatological care and treatment, gastroenterology, phytotherapy, analgesia and women's intimate health

Bayer's range of herbal medicines focuses mainly on two products: Euphytosis night and day

Financial Data

DUNS: 562038893

Legal Name: BAYER SAS

Address: 16 RUE JEAN MARIE LECLAIR , 69009 LYON 9EME

Number of employees: 103824 (2020)

Capital: 112 539 893 EUR


Financial Data:

Year Turnover (€) Net Profit (€) Fiscal Year End Fiscal Year Duration
2019 1 311 193 770 EUR 182 088 868 EUR 31/12/2019 12
2018 1 390 573 040 EUR -4 202 198 EUR 31/12/2018 12
2017 1 411 796 358 EUR 193 919 768 EUR 31/12/2017 12
2016 1 535 942 307 EUR 105 784 883 EUR 31/12/2016 12
2015 1 709 505 879 EUR 76 905 988 EUR 31/12/2015 12

Studies mentioning this company